Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M628Revenue $M318Net Margin (%)9.6Z-Score3.2
Enterprise Value $M677EPS $0.8Operating Margin %14.5F-Score7
P/E(ttm))18.9Cash Flow Per Share $1.3Pre-tax Margin (%)10.8Higher ROA y-yN
Price/Book2.610-y EBITDA Growth Rate %3.1Quick Ratio1.1Cash flow > EarningsY
Price/Sales1.95-y EBITDA Growth Rate %10.8Current Ratio2.2Lower Leverage y-yY
Price/Cash Flow8.9y-y EBITDA Growth Rate %31.1ROA % (ttm)7.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)16.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M30.6ROI % (ttm)25.6Gross Margin Increase y-yY

Gurus Latest Trades with CBM

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CBMJoel Greenblatt 2013-03-31 Sold Out -0.09%$11.27 - $12.79
($11.93)
$ 2068%Sold Out0
CBMJoel Greenblatt 2012-12-31 Buy 0.09%$9.34 - $13.96
($11.38)
$ 2076%New holding, 142352 sh.142,352
CBMJoel Greenblatt 2012-09-30 Sold Out -0.02%$9.01 - $13.01
($11.05)
$ 2081%Sold Out0
CBMJoel Greenblatt 2012-06-30 Buy 0.02%$5.96 - $9.16
($7.07)
$ 20183%New holding, 30208 sh.30,208
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CBM is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


CBM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Cavanagh ShawnEVP & COO 2014-09-11Sell56,251$22.56-10.33 view
KLOSK STEVEN MPresident & CEO 2014-09-03Sell126,257$22.01-8.09 view
Haskel William M.Senior Vice President 2014-09-02Sell9,400$21.94-7.79 view
KLOSK STEVEN MPresident & CEO 2014-08-19Sell4,702$22-8.05 view
Haskel William M.Senior Vice President 2014-08-07Sell28,100$22.5-10.09 view
KLOSK STEVEN MPresident & CEO 2014-08-07Sell1,200$22.52-10.17 view
WINSCHEL JAMES F JRDirector 2014-08-05Sell600$22.28-9.2 view
WINSCHEL JAMES F JRDirector 2014-08-05Buy600$22.28-9.2 view
SARGEN GREGORYEVP & CFO 2014-08-05Sell50,000$22.34-9.44 view
HENDRIX LEON J JRDirector 2014-02-28Sell23,000$20.090.7 view

Press Releases about CBM :

    Quarterly/Annual Reports about CBM:

    News about CBM:

    Articles On GuruFocus.com
    Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
    Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
    Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
    Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 


    More From Other Websites
    NYSE stocks posting largest percentage decreases Sep 22 2014
    Integra to Buy Medtronic's MicroFrance, Xomed; Shares Up Sep 22 2014
    Halozyme's PEGPH20 Study S1313 Clinical Hold Lifted by FDA Sep 19 2014
    ImmunoCellular Therapeutics (IMUC) Jumps: Stock Up 9% Sep 18 2014
    Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% Sep 18 2014
    Alder Biopharmaceuticals (ALDR) in Focus: Stock Up 5.2% Sep 18 2014
    Five Prime Therapeutics' Novel Target Licensed by Glaxo Sep 17 2014
    Regeneron Gets Breakthrough Therapy Status for Eylea Sep 17 2014
    Dendreon (DNDN) in Focus: Stock Up 9.4% Sep 16 2014
    Eli Lilly's Cyramza Scores in Colorectal Cancer Study Sep 15 2014
    Genomic Health Reveals Positive Oncotype DX Test Results Sep 15 2014
    Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% Sep 11 2014
    Xenoport/NIAAA Collaborate on Alcoholism Therapy Sep 10 2014
    ZIOPHARM Oncology (ZIOP) in Focus: Stock Rises 10.4% Sep 08 2014
    BioDelivery Sciences (BDSI) Jumps: Stock Rises 8.9% Sep 08 2014
    Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint Sep 05 2014
    Halozyme's PEGPH20 Program Gains Fast Track Designation Sep 05 2014
    XOMA Corporation (XOMA) Jumps: Stock Rises 6.2% Sep 05 2014
    Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab Sep 04 2014
    Cambrex To Present At Rodman & Renshaw 16th Annual Global Investment Conference Sep 03 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK